Danaher Corporation $DHR is M.D. Sass LLC’s 6th Largest Position

M.D. Sass LLC lessened its stake in shares of Danaher Corporation (NYSE:DHR) by 16.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 305,019 shares of the conglomerate’s stock after selling 60,370 shares during the quarter. Danaher accounts for about 5.5% of M.D. Sass LLC’s holdings, making the stock its 6th biggest holding. M.D. Sass LLC’s holdings in Danaher were worth $69,825,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently bought and sold shares of the stock. Bruce G. Allen Investments LLC boosted its stake in Danaher by 16.6% during the fourth quarter. Bruce G. Allen Investments LLC now owns 556 shares of the conglomerate’s stock worth $127,000 after buying an additional 79 shares during the period. Westpac Banking Corp boosted its stake in shares of Danaher by 13.6% in the fourth quarter. Westpac Banking Corp now owns 5,973 shares of the conglomerate’s stock valued at $1,367,000 after purchasing an additional 714 shares during the period. Rice Partnership LLC boosted its stake in shares of Danaher by 42.7% in the fourth quarter. Rice Partnership LLC now owns 38,210 shares of the conglomerate’s stock valued at $8,747,000 after purchasing an additional 11,439 shares during the period. Natixis Advisors LLC boosted its stake in shares of Danaher by 22.7% in the fourth quarter. Natixis Advisors LLC now owns 765,616 shares of the conglomerate’s stock valued at $175,265,000 after purchasing an additional 141,495 shares during the period. Finally, Pincus Capital Management LP purchased a new position in shares of Danaher in the fourth quarter valued at approximately $842,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

More Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher’s SCIEX unit introduced new product and software updates at ASMS, including the novus V55 system with SCIEX OS 5.0 and AI enablement tools, plus broader ZenoTOF platform expansions. These launches suggest continued innovation and support Danaher’s life sciences growth story. Article: SCIEX Launches the novus V55 System With SCIEX OS 5.0 Software and AI Enablement Tools
• Positive Sentiment: The SCIEX ZenoTOF platform updates and collaborations could improve workflow efficiency and strengthen Danaher’s competitive position in advanced analytical instruments. Article: SCIEX Advances the ZenoTOF Line With Platform-Wide Expansions in Software, Integrations, and Key Collaborations
• Neutral Sentiment: Recent commentary is focused on whether Danaher stock has become more attractive after its pullback, but the article frames this as a valuation debate rather than a clear catalyst. Article: Is It Time To Reassess Danaher (DHR) After Its Recent Share Price Weakness?
• Neutral Sentiment: A broader healthcare valuation piece highlighted large-cap healthcare stocks with expensive valuations, which may keep pressure on sentiment for Danaher if investors remain focused on multiples. Article: These 10 large-cap US healthcare companies carry the market’s most expensive valuations

Danaher Stock Down 2.2%

Shares of Danaher stock opened at $175.97 on Wednesday. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The company has a 50 day moving average of $181.91 and a 200 day moving average of $207.20. The company has a quick ratio of 1.52, a current ratio of 1.87 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $124.54 billion, a P/E ratio of 34.04, a P/E/G ratio of 2.40 and a beta of 0.81.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, April 20th. The conglomerate reported $2.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The company had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $6 billion. During the same quarter in the previous year, the firm earned $1.88 earnings per share. The firm’s quarterly revenue was up 3.7% on a year-over-year basis. As a group, research analysts forecast that Danaher Corporation will post 8.43 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be paid a $0.40 dividend. The ex-dividend date is Friday, June 26th. This represents a $1.60 dividend on an annualized basis and a yield of 0.9%. Danaher’s payout ratio is currently 30.95%.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. Royal Bank Of Canada assumed coverage on shares of Danaher in a research note on Thursday, May 14th. They issued an “outperform” rating and a $200.00 price objective for the company. Wall Street Zen lowered shares of Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. TD Cowen lowered their price objective on shares of Danaher from $245.00 to $240.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. Guggenheim lowered their price objective on shares of Danaher from $275.00 to $235.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. Finally, Wolfe Research lowered shares of Danaher from an “outperform” rating to a “peer perform” rating in a research note on Monday. Nineteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, Danaher has an average rating of “Moderate Buy” and a consensus price target of $238.24.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.